EQUITY RESEARCH - COMPANY REPORT

BANGKOK CHAIN HOSPITAL THAILAND / HEALTH CARE SERVICES

Growth is just around the corner

- Expect 3Q23 core profit to jump by 45% q-q to THB412m due to a strong cash patient volume and improving EBITDA margin.
- 2024 earnings growth is promising from a turnaround of three new loss-making hospitals and a reduction of one-off expenses.
- Maintain BUY with a higher DCF-TP of THB24.5/shr.

Expect 3Q23 to be the first y-y growth in the past five quarters

We expect 3Q23 revenue to grow by 11% q-q. Cash patient revenue should grow by 14% q-q due to influenza and flu outbreaks during the rainy season and should exceed pre-Covid by 35%. SSO revenue should grow by 3% q-q due to a higher payment rate (THB1,808/head/year from THB1,640 effective May 2023). EBITDA margin should significantly improve to 25% in 3Q23 (vs 22% in 2Q23). We estimate one-off expenses to reduce q-q from THB122m (THB63 FX loss and THB59m provision expenses from UCEP Covid) in 2Q23 to THB60-70m (THB20-30m FX loss and THB40m provision expenses). As a result, we forecast core profit to jump 45% q-q to THB412m, exceeding pre-Covid by 2%.

Earnings momentum should continue in 4Q23

We expect 4Q23 to remain strong. FX loss (THB100-110m in 9M23E) would disappear given that BCH and its partner have injected capital of THB482m in KIH Vientiane to repay the entire THB term loan in Sep. In addition, BCH would book an additional gain of cTHB30-50m from chronic disease treatments in 4Q23. As a result, we see a scope of upside from our 2023 core profit forecast subjected to 3Q23 results scheduled for a release on 9 Nov.

Clearer earnings growth visibility in 2024

We expect strong earnings growth of 25% in 2024, premised on a turnaround of three new hospitals. We estimate three new hospitals to contribute a loss of THB200-240m in 2023, and they should reach breakeven in 2024, with KIH Vientiane as the first to turn profitable. In addition, one-off items totaling THB200-230m, including FX loss of THB100-110m and THB100-120m of UCEP Covid, should significantly reduce in 2024.

Cheap valuation; top pick in the Healthcare sector

We maintain our forecast and roll forward our DCF-based valuation to 2024E and derive a new TP of THB24.5/shr. BCH trades at 29x 2024E P/E, its 5-year average. A strong earnings recovery in 3Q23 would turn market attention to BCH. BCH is now our top pick in the Healthcare sector as we see a promising EBITDA margin recovery outlook from the lowest of 22% in 1H23 to 24% in 2024.



Teerapol Udomvej, CFA Fundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969 FSSIA ESG rating




UNCHANGED

TARGET PRICE	THB24.50
CLOSE	THB20.00
UP/DOWNSIDE	+22.5%
PRIOR TP	THB22.50
CHANGE IN TP	+8.9%
TP vs CONSENSUS	+15.6%

KEY STOCK DATA

YE Dec (THB m)	2022	2023E	2024E	2025E
Revenue	18,827	12,851	14,089	15,342
Net profit	3,039	1,357	1,697	2,011
EPS (THB)	1.22	0.54	0.68	0.81
vs Consensus (%)	-	(7.4)	(3.1)	3.3
EBITDA	5,059	2,956	3,424	3,882
Recurring net profit	3,039	1,357	1,697	2,011
Core EPS (THB)	1.22	0.54	0.68	0.81
Chg. In EPS est. (%)	-	-	-	-
EPS growth (%)	(55.6)	(55.4)	25.1	18.5
Core P/E (x)	16.4	36.8	29.4	24.8
Dividend yield (%)	7.0	2.5	1.5	1.9
EV/EBITDA (x)	10.3	17.0	14.3	12.3
Price/book (x)	4.0	4.0	3.7	3.4
Net debt/Equity (%)	9.2	(6.1)	(13.9)	(21.2)
ROE (%)	23.9	10.9	13.0	14.3



Sources: Bloomberg consensus; FSSIA estimates

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT



Investment thesis

BCH is a leading service provider under the Social Security Office (SSO) scheme with a 5% market share. It likely benefited the most from Covid-19 services, including screening and treatments for Covid patients.

After Covid-19 has subsided, we think World Medical Hospital (WMC) should continue to capture rising demand from medical tourists. Normally, 50% of WMC's revenue comes from international patients, especially from the Middle East. We expect BCH to capture the strong recovery of that patient segment.

In 2020-2021, BCH opened three new hospitals, which continue to produce a loss contribution. However, their operation is improving, and all three hospitals should turn profitable by 2025, leading to a better EBITDA and NPM.

Company profile

The company operates its business as a group, providing healthcare services for both cash patients and patients under the social security scheme.

www.bangkokchainhospital.com

Principal activities (revenue, 2022)

- Cash patient revenue 49.8 %
- SSO patient revenue 17.9 %
- NHSO patient revenue 32.3 %

Source: Bangkok Chain Hospital

Major shareholders

- Chalerm Harnphanich 32.6 %
- Thai NVDR 8.8 %
- Somporn Harnphanich 6.8 %
- Others 51.8 %

Source: Bangkok Chain Hospital

Catalysts

Key potential growth drivers include 1) more SSO-registered members; 2) rising demand from medical tourists; and 3) an improving EBITDA margin led by new hospitals.

Risks to our call

Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests, or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following a limited SSO budget.

Event calendar

 Date
 Event

 Nov 2023
 3Q23 results announcement

Key assumptions

	2023E	2024E	2025E
	(%)	(%)	(%)
SSO volume growth	6	3	3
SSO revenue / patient growth	5	5	5
OPD volume growth	(36)	5	5
OPD revenue / patient growth	30	5	5
IPD volume growth	10	5	5
IPD revenue / patient growth	7	5	3

Source: FSSIA estimates

Earnings sensitivity

- For every 1% increase in patient volume, we project 2023 earnings would rise by 2%, and vice versa, all else being equal.
- For every 1% increase in EBITDA margin, we project 2023 earnings would rise by 5%, and vice versa, all else being equal.

Source: FSSIA estimates




Exhibit 1: 3Q23 results preview

	3Q22	4Q22	1Q23	2Q23	3Q23E	Char	ıge	2023E	Chg
	(THB m)	(q-q %)	(y-y %)	(THB m)	(у-у %				
Sales	3,429	2,788	2,674	2,849	3,160	11	(8)	12,851	(32
COGS (incl. depreciation)	(3,519)	(1,876)	(1,936)	(1,989)	(2,180)	10	(38)	(8,971)	(30
Gross profit	(90)	912	738	860	980	14	(1,184)	3,880	(36
SG&A	(420)	(511)	(398)	(495)	(460)	(7)	9	(1,928)	(1
Operating profit	(511)	401	340	365	520	42	(202)	1,953	(52
Net other income	27	13	25	28	32	13	19	90	(2
Interest expense	(35)	(34)	(28)	(24)	(24)	0	(30)	(125)	(20
Pretax profit	(519)	380	337	369	527	43	202	1,918	(53
Income Tax	74	(101)	(70)	(86)	(95)	10	(228)	(384)	(57
Associates	0	(1)	(1)	2	0			2	n/a
Minority interest	41	(8)	(12)	(1)	(20)			(179)	5
Core profit	(403)	270	254	284	412	45	202	1,357	(55
Extraordinaries, GW & FX	0	0	0	0	0				
Reported net profit	(403)	270	254	284	412	45	202	1,357	(55
Outstanding shares (m)	2,494	2,494	2,494	2,494	2,494	0	0	2,494	(
Core EPS (THB)	(0.16)	0.11	0.10	0.11	0.17	45	202	0.54	(55
EPS (THB)	(0.16)	0.11	0.10	0.11	0.17	45	202	0.54	(55
COGS (excl. depreciation)	3,279	1,636	1,698	1,755	1,942	11	(41)	7,968	(33
Depreciation	240	240	238	234	239	2	(1)	1,003	
EBITDA	(244)	654	603	627	790	26	424	3,046	(41
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(ppt
Gross margin	(3)	33	28	30	31	1	34	30	(2
SG&A/Revenue	12	18	15	17	15	(3)	2	15	
EBITDA margin	(7)	23	23	22	25	3	32	23	(4
Net profit margin	(12)	10	9	10	13	3	25	11	(6
Operating stats	(y-y %)	(y-y %)	(y-y %)	(y-y %)					
Cash-OPD revenue growth	45	(38)	(51)	(21)					
Cash-OPD volume growth	(23)	(63)	(74)	(47)					
Cash-OPD revenue per head growth	17	50	66	49					
Cash-IPD revenue growth	5	(9)	(20)	13					
Cash-IPD volume growth	(97)	(71)	(77)	(56)					
Cash-IPD revenue per head growth	402	(26)	7	25					
SSO revenue growth	37	7	14	16					
SSO registered member ('000)	994	1,012	1,013	1,012					
SSO registered member growth	11	13	8	4					
SSO revenue per head growth	45	(13)	(43)	(64)					

Sources: BCH; FSSIA estimates

Exhibit 2: Non-Covid general patient revenue



Source: BCH; FSSIA estimates

Exhibit 4: EBITDA margin






Exhibit 3: SSO revenue, quarterly



Source: BCH; FSSIA estimates

Exhibit 5: Core profit



Sources: BCH; FSSIA estimates

Note: 3Q22 excludes Moderna write-off Sources: BCH; FSSIA estimates

Exhibit 6: DCF-derived TP

Cost of equity assumptions	(%)	Cost of debt assumptions	(%)
Risk-free rate	3.0	Pre-tax cost of debt	4.0
Market risk premium	8.0	Marginal tax rate	20.0
Stock beta	1.0		
Cost of equity, Ke	10.6	Net cost of debt, Kd	3.2
Weight applied	70.0	Weight applied	30.0
WACC	8.4		

DCF valuation estimate	(THB b)	(THB/share)	Comments
NPV	22.9	9.2	WACC 8.4%, Risk-free rate 3%, Risk premium 8%
Terminal value	37.4	15.0	Terminal growth 3%
Cash & liquid assets	5.1	2.1	At end-2023E
Investments	0.0	0.0	At end-2023E
Debt	(3.1)	(1.2)	At end-2023E
Minorities	(1.2)	(0.5)	At end-2023E
Residual ordinary equity	61.2	24.5	

Source: FSSIA estimates

FINANSIA

Exhibit 7: Historical P/E band







Sources: Bloomberg; FSSIA estimates

Exhibit 9: Peer comparisons as of 2 Nov 2023

Company	BBG	Rec	;	Share price	9	Market	P	'E	RC)E	PBV		- EV/ EB	ITDA -
			Current	Target	Upside	Сар	23E	24E	23E	24E	23E	24E	23E	24E
			(LCY)	(LCY)	(%)	(USD m)	(x)	(x)	(%)	(%)	(x)	(x)	(x)	(x)
Thailand														
Bangkok Dusit Med Service	BDMS TB	BUY	26.75	34.50	29.0	11,824	31.6	27.8	14.5	15.4	4.5	4.1	17.6	15.7
Bumrungrad Hospital	BH TB	BUY	256.00	300.00	17.2	5,660	30.1	28.8	31.1	28.0	8.6	7.6	20.0	19.0
Bangkok Chain Hospital	BCH TB	BUY	20.00	24.50	22.5	1,387	36.8	29.4	10.9	13.0	4.0	3.7	17.0	14.3
Chularat Hospital	CHG TB	BUY	3.18	4.00	25.8	973	29.5	25.5	15.7	17.4	4.6	4.3	17.0	14.8
Praram 9 Hospital	PR9 TB	BUY	15.80	22.00	39.2	346	24.6	20.6	10.4	11.6	2.5	2.3	11.3	9.5
Thonburi Healthcare Group	THG TB	REDUCE	61.50	55.00	(10.6)	1,450	44.0	38.7	11.4	12.4	4.9	4.7	24.4	21.8
Ramkhamhaeng Hospital	RAM TB	BUY	41.75	60.00	43.7	1,393	25.5	21.9	10.0	11.2	2.5	2.4	29.1	25.4
Rajthanee Hospital	RJH TB	n/a	26.25	n/a	n/a	218	19.2	18.1	18.3	17.9	5.3	3.3	12.4	11.5
Ekachai Medical Care	EKH TB	n/a	7.70	n/a	n/a	150	22.1	20.3	11.1	11.6	5.6	2.4	12.4	11.3
Thailand average						23,401	29.3	25.7	14.8	15.4	4.7	3.9	17.9	15.9
Regional														
Ramsay Health Care	RHC AU	n/a	50.29	n/a	n/a	7,412	33.9	34.7	8.6	8.1	2.8	2.7	11.6	10.8
Ihh Healthcare Bhd	IHH SP	n/a	1.72	n/a	n/a	11,098	32.7	30.1	6.2	6.4	2.3	1.9	14.1	13.5
Ryman Healthcare	RYM NZ	n/a	5.77	n/a	n/a	2,337	11.5	12.1	7.5	7.8	1.3	0.8	13.4	12.8
Apollo Hospitals Enterprise	APHS IN	n/a	4,887	n/a	n/a	8,439	83.6	67.2	13.8	15.6	19.3	10.9	34.7	29.6
Kpj Healthcare Berhad	KPJ MK	n/a	1.26	n/a	n/a	1,157	25.7	23.3	9.4	9.9	2.8	2.4	11.6	10.9
Raffles Medical Group	RFMD SP	n/a	1.20	n/a	n/a	1,637	18.8	18.8	11.5	11.0	2.6	2.1	10.2	10.2
Mitra Keluarga Karyasehat	MIKA IJ	n/a	2,700	n/a	n/a	2,426	38.8	33.2	17.2	18.4	7.9	6.5	24.9	21.4
Aier Eye Hospital Group	300015 CH	n/a	18.30	n/a	n/a	23,339	48.7	38.3	18.2	19.7	19.6	8.3	28.6	22.9
Regional average						57,846	36.7	32.2	11.6	12.1	7.3	4.5	18.6	16.5
Overall average						81,246	32.8	28.8	13.3	13.9	5.9	4.2	18.3	16.2

Sources: Bloomberg; FSSIA estimates

FINANSIA

Financial Statements

Bangkok Chain Hospital

Profit and Loss (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025E
Revenue	21,405	18,827	12,851	14,089	15,342
Cost of goods sold	(10,561)	(12,772)	(8,971)	(9,691)	(10,427)
Gross profit	10,844	6,055	3,880	4,399	4,915
Other operating income	-	-	-	-	-
Operating costs	(1,469)	(1,946)	(1,928)	(2,015)	(2,133)
Operating EBITDA	10,248	5,059	2,956	3,424	3,882
Depreciation	(874)	(950)	(1,003)	(1,040)	(1,099)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	9,374	4,109	1,953	2,384	2,783
Net financing costs	(147)	(148)	(121)	(108)	(94)
Associates	2	0	2	2	2
Recurring non-operating income	127	84	88	92	96
Non-recurring items	0	0	0	0	0
Profit before tax	9,354	4,046	1,920	2,368	2,785
Тах	(1,846)	(888)	(384)	(473)	(557)
Profit after tax	7,507	3,157	1,536	1,895	2,228
Minority interests	(661)	(118)	(179)	(197)	(217)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	6,846	3,039	1,357	1,697	2,011
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	6,846	3,039	1,357	1,697	2,011
Per share (THB)					
Recurring EPS *	2.75	1.22	0.54	0.68	0.81
Reported EPS	2.75	1.22	0.54	0.68	0.81
DPS	0.33	1.40	0.50	0.30	0.37
Diluted shares (used to calculate per share data)	2,494	2,494	2,494	2,494	2,494
Growth					
Revenue (%)	139.8	(12.0)	(31.7)	9.6	8.9
Operating EBITDA (%)	306.3	(50.6)	(41.6)	15.8	13.4
Operating EBIT (%)	438.6	(56.2)	(52.5)	22.1	16.7
Recurring EPS (%)	456.9	(55.6)	(55.4)	25.1	18.5
Reported EPS (%)	456.9	(55.6)	(55.4)	25.1	18.5
Operating performance					
Gross margin inc. depreciation (%)	50.7	32.2	30.2	31.2	32.0
Gross margin exc. depreciation (%)	54.7	37.2	38.0	38.6	39.2
Operating EBITDA margin (%)	47.9	26.9	23.0	24.3	25.3
Operating EBIT margin (%)	43.8	21.8	15.2	16.9	18.1
Net margin (%)	32.0	16.1	10.6	12.0	13.1
Effective tax rate (%)	19.7	22.0	20.0	20.0	20.0
Dividend payout on recurring profit (%)	12.0	114.9	91.9	44.0	46.4
Interest cover (X)	64.5	28.4	16.9	23.0	30.6
Inventory days	12.9	12.3	13.9	10.7	10.8
Debtor days	42.9	49.3	43.7	39.9	36.6
Creditor days	40.3	41.0	49.9	38.6	38.7
Operating ROIC (%)	51.4	21.4	11.7	15.6	18.4
ROIC (%)	50.1	21.0	11.7	15.3	18.0
ROE (%)	68.9	23.9	10.9	13.0	14.3
ROA (%)	35.5	14.2	8.3	10.1	11.2
* Pre-exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2021	2022	2023E	2024E	2025E
Cash patient revenue	7,476	9,372	9,099	10,032	10,954
SSO patient revenue	2,905	3,371	3,752	4,058	4,388
NHSO patient revenue	11,023	6,084	0	0	C

Sources: Bangkok Chain Hospital; FSSIA estimates

Financial Statements

Bangkok	Chain	Hospital	
Durighton	Onuni	rioopitai	

cash Flow (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025
ecurring net profit	6,846	3,039	1,357	1,697	2,01
epreciation	874	950	1,003	1,040	1,099
ssociates & minorities	-	-	-	-	
ther non-cash items	660	24	176	197	21
change in working capital	(2,204)	1,459	1,786	125	12
ash flow from operations	6,175	5,471	4,322	3,059	3,45
Capex - maintenance	(678)	(984)	(896)	(986)	(1,074
Capex - new investment	-	- 2	-	- 0	
let acquisitions & disposals	(1)	2	0	U	(
Other investments (net) Cash flow from investing	(679)	(982)	(896)	(986)	(1,074
Dividends paid	(821)	(3,491)	(1,247)	(746)	(1,074) (933
quity finance	(821)	(3,491)	(1,247)	(740)	(933
Debt finance	(274)	(3,153)	0	(800)	
Other financing cash flows	(274)	(462)	(99)	(109)	(119
cash flow from financing	(1,186)	(7,106)	(1,346)	(1,655)	(1,053
lon-recurring cash flows	(.,,	(.,,	(.,	(1,000)	(1,000
Other adjustments	0	0	0	0	(
let other adjustments	Ő	ů	Ő	Ő	
lovement in cash	4,310	(2,616)	2,080	418	1,32
ree cash flow to firm (FCFF)	5,647.32	4,645.31	3,550.83	2,188.14	2,480.20
ree cash flow to equity (FCFE)	5,131.91	875.07	3,327.20	1,164.45	2,258.9
	· · ·				,
Per share (THB)	0.00	1.00	1 40	0.00	0.00
CFF per share	2.26	1.86	1.42	0.88	0.9
CFE per share Recurring cash flow per share	2.06 3.36	0.35 1.61	1.33 1.02	0.47 1.18	0.9 1.3
	3.30	1.01	1.02		1.0
Balance Sheet (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025
angible fixed assets (gross)	19,417	20,274	21,174	22,160	23,234
ess: Accumulated depreciation	(7,175)	(7,992)	(8,995)	(10,035)	(11,134
angible fixed assets (net)	12,243	12,282	12,179	12,125	12,10
ntangible fixed assets (net)	540	425	425	425	42
ong-term financial assets	-	-	-	-	
nvest. in associates & subsidiaries	34	32	32	32	3:
Cash & equivalents	5,256	2,640	4,720	5,139	6,464
/C receivable	3,547	1,539	1,539	1,539	1,539
nventories	437	362	244	265	28
Other current assets	4,302	2,294	124	135	148
Current assets	13,541	6,835	6,626	7,077	8,43
Other assets	26	223	223	223	223
otal assets	26,384	19,796	19,485	19,882	21,21
Common equity	12,980	12,445	12,555	13,506	14,58
linorities etc.	1,326	1,065	1,146	1,234	1,33
otal shareholders' equity	14,306	13,510	13,700	14,740	15,91
ong term debt	6,791	3,888	3,888	3,088	3,08
Other long-term liabilities	170	163	163	163	16
ong-term liabilities	6,961	4,051	4,051	3,251	3,25
/C payable	1,358	1,300	876	951	1,020
Short term debt	250	0	0	0	(
Other current liabilities	3,510	935	856	939	1,02
Current liabilities	5,117	2,235	1,733	1,890	2,04
otal liabilities and shareholders' equity	26,384	19,796	19,485	19,882	21,21
let working capital	3,418	1,959	173	49	(77
nvested capital	16,260	14,921	13,032	12,853	12,70
Includes convertibles and preferred stock which is being	g treated as debt				
Per share (THB)					
Book value per share	5.20	4.99	5.03	5.42	5.8
angible book value per share	4.99	4.82	4.86	5.25	5.6
inancial strength					2.0
let debt/equity (%)	12.5	9.2	(6.1)	(13.9)	(21.2
let debt/total assets (%)	6.8	9.2 6.3	(4.3)	(10.3)	(21.2)
Current ratio (x)	2.6	3.1	(4.3)	3.7	(15.8
F interest cover (x)	35.9	6.9	28.5	3.7 11.8	4. 25.
aluation	2021	2022	2023E	2024E	2025
Recurring P/E (x) *	7.3	16.4	36.8	29.4	24.
Recurring P/E @ target price (x) *	8.9	20.1	45.0	36.0	30.
eeunig : = @ taiget price (A)	7.3	16.4	36.8	29.4	24.
		7.0	2.5	1.5	1.
Reported P/E (x) Dividend yield (%)	1.6				
Reported P/E (x)	1.6 3.8	4.0	4.0	3.7	3.4
Reported P/E (x) Dividend yield (%) Yrice/book (x)			4.0 4.1	3.7 3.8	
Reported P/E (x) Dividend yield (%)	3.8	4.0			3.
Reported P/E (x) Dividend yield (%) Price/book (x) Price/tangible book (x)	3.8 4.0	4.0 4.1	4.1	3.8	3.4 3.5 12.5 15.5

Sources: Bangkok Chain Hospital; FSSIA estimates



Bangkok Chain Hospital PCL (BCH TB)

FSSIA ESG rating $\star \star \star$

39.71 /100

Exhibit 10: FSSIA ESG score implication

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
$\star\star\star\star$	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 11: ESG – peer comparison

	FSSIA	Domestic ratings						Global ratings						Bloomberg		
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score	
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17	
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94	
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60	
BDMS	74.00	Y	Y	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92	
BH	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79	
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24	
PR9	54.08		Y	Y	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90	
PRINC	18.00				4.00	4.00	Certified									
RAM	11.75				3.00			High								
THG	18.75				5.00	5.00		High								
VIBHA	20.88				4.00	3.00	Declared	High					17.00			

Sources: <u>SETTRADE.com</u>; FSSIA's compilation

Exhibit 12: ESG score by Bloomberg

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	0.56	0.71	0.75	0.72	0.80	0.85	2.36	3.52
BESG environmental pillar score	0.00	0.00	0.00	0.00	0.38	0.38	2.96	4.63
BESG social pillar score	0.00	0.22	0.22	0.22	0.22	0.22	1.70	3.47
BESG governance pillar score	2.35	2.41	2.62	2.50	2.41	2.63	3.19	2.91
ESG disclosure score	18.06	19.81	19.81	19.81	20.08	20.08	31.27	47.60
Environmental disclosure score	0.00	0.42	0.42	0.42	1.24	1.24	20.57	46.18
Social disclosure score	3.17	10.52	10.52	10.52	10.52	10.52	18.53	41.96
Governance disclosure score	50.87	48.37	48.37	48.37	48.37	48.37	54.64	54.64
Environmental								
Emissions reduction initiatives	No	No	No	No	Yes	Yes	Yes	Yes
Climate change policy	No	No	No	No	No	No	Yes	Yes
Climate change opportunities discussed	No							
Risks of climate change discussed	No							
GHG scope 1	_	_	_	_	_	_	1	2
GHG scope 2 location-based	_	_	_	_	_	_	5	6
GHG Scope 3	_	_	_	_	_	_	_	_
Carbon per unit of production	_	_	_	_	_	_	_	_
Biodiversity policy	No							
Energy efficiency policy	No	Yes						
Total energy consumption	_	_	_	_	_	_	10	12
Renewable energy use	—	_	_	_	_	_	_	_
Electricity used	_	_	_	_	_	_	10	12
Fuel used - natural gas	_	_	_	_	_	_	_	_

Sources: Bloomberg; FSSIA's compilation

Exhibit 13: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No							
Waste reduction policy	No	No	No	No	Yes	Yes	Yes	Yes
Hazardous waste	—	_	_	_	_	_	_	0
Total waste	—	_	_	_	_	_	_	0
Waste recycled	_	—	—	—	—	—	—	0
Waste sent to landfills	_	—	_	_	—	—	_	0
Environmental supply chain management	No	Yes						
Water policy	No	No	No	No	No	No	Yes	Yes
Water consumption	_	-	-	_	-	-	-	-
Social								
Human rights policy	No	Yes						
Policy against child labor	No	Yes						
Quality assurance and recall policy	No	Yes						
Consumer data protection policy	No							
Equal opportunity policy	Yes							
Gender pay gap breakout	No							
Pct women in workforce	—	—	_	—	—	_	_	76
Pct disabled in workforce	—	_	_	_	_	_	_	1
Business ethics policy	Yes							
Anti-bribery ethics policy	No	Yes						
Health and safety policy	No	Yes						
Lost time incident rate - employees	_	—	—	—	—	—	0	0
Total recordable incident rate - employees	_	—	—	—	—	—	0	1
Training policy	No	Yes						
Fair remuneration policy	No	Yes						
Number of employees – CSR	—	—	—	—	—	—	8,597	8,877
Employee turnover pct	—	—	—	—	—	—	—	43
Total hours spent by firm - employee training	—	—	—	—	—	—	—	54,702
Social supply chain management	No	Yes						
Governance								
Board size	10	10	10	12	12	12	12	11
No. of independent directors (ID)	4	4	4	4	4	4	4	4
No. of women on board	3	3	3	4	4	3	3	3
No. of non-executive directors on board	5	5	5	5	5	5	5	5
Company conducts board evaluations	Yes							
No. of board meetings for the year	6	5	6	5	5	6	6	6
Board meeting attendance pct	93	94	90	96	100	99	94	97
Board duration (years)	—	—	—	—	—	—	—	-
Director share ownership guidelines	No							
Age of the youngest director	28	29	30	29	30	31	32	33
Age of the oldest director	72	73	74	75	76	77	78	79
No. of executives / company managers	5	5	5	5	5	7	7	6
No. of female executives	1	_	—	_	_	—	_	—
Executive share ownership guidelines	No							
Size of audit committee	3	3	3	3	3	3	3	3
No. of ID on audit committee	3	3	3	3	3	3	3	3
Audit committee meetings	4	4	5	5	5	5	5	5
Audit meeting attendance %	100	92	100	93	100	100	93	100
Size of compensation committee	0	0	0	0	0	0	0	0
No. of ID on compensation committee	—	_	—	_	_	—	—	_
No. of compensation committee meetings	—	_	—	_	_	_	—	_
Compensation meeting attendance %	_	_	_	_	_	_	_	_
Size of nomination committee	0	0	0	0	0	0	0	0
No. of nomination committee meetings	—	_	_	_	_	_	_	_
Nomination meeting attendance %	_	_	_	_	_	_	_	_
Sustainability governance								
Verification type	No							

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodology				Rating							
The Dow Jones Sustainability Indices (<u>DJSI</u>) By S&P Global	process based o from the annual s	n the compa S&P Global	ansparent, rules-based o anies' Total Sustainabilit Corporate Sustainabilit ies within each industry	Be a member and invited to the annual S&P Global Corporate Sustainability Assessment (CSA) for DJSI. Companies with an S&P Global ESG Score of less than 45% of the S&P Global ESG Score of the highest scoring company are disqualified. The constituents of the DJSI indices are selected from the Eligible Universe.								
Sustainability Investment List (<u>THSI</u>) by The Stock Exchange of Thailand (<u>SET</u>)	managing busine Candidates must conditions: 1) no and 2) free float >15% of paid-up score of below 7 executives' wron	ess with trar t pass the p irregular tra of >150 sha capital. Sor 0%; 2) inde gdoing rela	y in Environmental and sparency in Governance reemptive criteria, with t iding of the board memil reholders, and combine ne key disqualifying crit bendent directors and fr ed to CG, social & envir nd 5) earnings in red fo	To be eligible for THSI inclusion , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against the nature of the relevant industry and materiality. SETTHSI Index is extended from the THSI companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight at maximum, and no cap for number of stocks.								
CG Score by Thai Institute of Directors Association (<u>Thai IOD</u>)	annually by the T	Thai IOD, wi The results	n sustainable developrr th support from the Stor are from the perspective	Scores are rated in six categories: 5 for Excellent (90-100), 4 for Very Good (80-89), 3 for Good (70-79), 2 for Fair (60-69), 1 for Pass (60-69), and not rated for scores below 50. Weightings include: 1) the rights; 2) and equitable treatment of shareholders (weight 25% combined); 3) the role of stakeholders (25%); 4) disclosure & transparency (15%); and 5) board responsibilities (35%).								
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment are inc transparent and out of five the CC assessment crite the meeting date advance circulation rights can be exerci- transparency and w	corporated in sufficiently of componer eria cover A(e (45%), and of sufficient in ised. The sect erifiability; and	ich shareholders' rights to business operations lisclosed. All form impoi ts to be evaluated annu GM procedures before t after the meeting (10% information for voting; and 2, and assesses 1) the ease of a 3) openness for Q&A. The ain discussion issues, resol	The scores are classified into four categories: 5 for Excellent (100), 4 for Very Good (90-99), 3 for Fair (80-89), and not rated for scores below 79.								
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishment of policies. The Cer (Companies decidir Declaration of Inten Certification, includir	key control rtification is ng to become it to kick off ar ing risk asses loyees, estab	ecklist include corruptions, and the monitoring and the monitoring and good for three years. a CAC certified member state 18-month deadline to submement, in place of policy and issment, in place of policy and takeholders.)	nd developing of art by submitting a mit the CAC Checklist for d control, training of	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.							
<u>Morningstar</u> Sustainalytics					A company's ESG risk rating score is the sum of unmanaged risk. The more risk is unmanaged, the higher ESG risk is scored.							
information, company feedback, ESG controversies, issuer feedback on draft ESC reports, and quality & peer reviews.					NEGL	Low	Medium	High	Severe			
						10-20	20-30	30-40	40+			
<u>ESG Book</u>	positioned to out the principle of fin helps explain fut	perform ove nancial mat ure risk-adju eatures with	stainable companies tha r the long term. The me eriality including informa isted performance. Mate higher materiality and r r basis.	ethodology considers ation that significantly eriality is applied by	The total ESG score is calculated as a weighted sum of the features scores using materiality-based weights. The score is scaled between 0 and 100 with higher scores indicating better performance.							
MSCI			easure a company's ma laggards according to t							ogy to		
		.571-10.000	Leader:									
	AA	7.143-8.570	Leauer.	leading its industry in it	n managing the most significant ESG risks and opportunities							
		5.714-7.142		a mixed or unexception	nal track record of managing the most significant ESG risks and opportunities relative to							
		4.286-5.713	Average:	industry peers								
		2.857-4.285 1.429-2.856										
		0.000-1.428	Laggard:	sed on its high exposure and failure to manage significant ESG risks								
Moody's ESG solutions	Moody's assesse believes that a c	es the degre ompany inte	e to which companies t grating ESG factors into shareholders over the n	o its business model an								
Refinitiv ESG rating	based on publicly	y available a	nd objectively measure a and auditable data. The publicly. <i>(Score ratings ar</i>	score ranges from 0 to	100 on relative	ESG perform	nance and insu	fficient degre				
S&P Global			is a relative score meas the same industry class				nt of ESG risk	s, opportuniti	es, and impac	sts		
Bloomberg	ESG Score Bloomberg score evaluating the company's aggregated Environmental, Social and Governance (ESG) performance. The score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean) of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best.											
Bloomberg	ESG Disclosure		Disclosure of a company				•	•				

Source: FSSIA's compilation

FINANSIA

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

Company	Ticker	Price	Rating	Valuation & Risks
Bangkok Chain Hospital	BCH TB	THB 20.00	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following a limited SSO budget.
Bangkok Dusit Medical Services	BDMS TB	THB 26.75	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher-than-expected capex and opex for CoE projects.
Bumrungrad Hospital	ВН ТВ	THB 256.00	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher medical fee discount promotions, leading to a weaker EBITDA margin.
Chularat Hospital	CHG TB	THB 3.18	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.
Praram 9 Hospital	PR9 TB	THB 15.80	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) higher-than-expected expenses from its new building.
Thonburi Healthcare Group	THG TB	THB 61.50	REDUCE	Upside risks to our DCF-based target price include 1) a new Covid wave from a new variant; and 2) big-lot sales of Jin Wellbeing County units.
Ramkhamhaeng Hospital	RAM TB	THB 41.75	BUY	Downside risks to our DCF-based target price include 1) weak patient volumes following the economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) losses from its subsidiary companies.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 02-Nov-2023 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months. **Neutral.** The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months. **Underweight.** The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

